The therapeutic potential of bee venom-derived Apamin and Melittin conjugates in cancer treatment: A systematic review
Melittin and phospholipase A2: Promising anti-cancer candidates from bee venom
An Updated Review Summarizing the Anticancer Efficacy of Melittin from Bee Venom in Several Models of Human Cancers
A multicenter open-label randomized phase II trial of paclitaxel plus EP-100, a novel LHRH receptor-targeted, membrane-disrupting peptide, versus paclitaxel alone for refractory or recurrent ovarian cancer
Enhanced immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer
GnRH-R-Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition
Targeted Oncolytic Peptide for Treatment of Ovarian Cancers
Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors
Learn Why Targeted Oncolytic Peptides (TOPs) Are a Promising Treatment for Multiple Cancer Types
Interested in learning more about the A28 targeted oncolytic peptide platform? We would be pleased to have an opportunity to share our compelling story, platform, pipeline, and data with you.
Contact Us